Protection against melanoma by vaccination with Bacille Calmette-Guerin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control.
A multicentre case-control study conducted by the FEBrile Infections and Melanoma (FEBIM) group has demonstrated a reduced risk of melanoma associated with Bacille Calmette-Guerin (BCG) and/or vaccinia vaccination in early childhood and/or with infectious diseases later in life. This has led to the recognition of a new risk indicator of melanoma; namely 'not being vaccinated with either with BCG or vaccinia'. On the basis of these findings, we propose a hypothesis of immune surveillance for melanoma induced or enhanced by prior contacts with pathogens unexpectedly cross-reactive to a cellular 'marker of melanoma risk'. The reduced risk of melanoma due to BCG and vaccinia, as well as certain common causes of infectious disease, is shown to be associated with antigenic determinants exhibiting sequence homologies with the HERV-K-MEL-antigen. The latter is a product of a pseudo-gene that is closely associated with the env-gene of the endogenous human retrovirus K (HERV-K). A suppressive immune reaction appears to inhibit the expression of endogenous retroviral genes, such as the HERV-K env-gene, that could otherwise result in malignant transformation years or even decades later. The HERV-K env-protein has homologous amino acid sequences with the human nuclear factor Oxygen Responsive Element Binding Protein (OREBP) that controls the expression of glutathione peroxidase. The formation of this and other redox-enzymes, needed to maintain appropriate levels of the normal intracellular redox potential, seems to be suppressed by the OREBP-homologous protein. The present hypothesis is in accordance with the concept that immune dysregulation due to adverse environmental impacts is a risk factor not only for some autoimmune disorders, as previously described, but also for certain malignancies such as melanoma.
Krone
Bernd
B
Department of Virology, University of Göttingen, Kreuzbergring 57, D-37075 Göttingen, Germany. bkrone@gwdg.de
Kölmel
Klaus F
KF
Henz
Beate M
BM
Grange
John M
JM
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000917:Antibody Formation; D000956:Antigens, Viral / Q000276:immunology; D001500:BCG Vaccine / Q000276:immunology*; D016022:Case-Control Studies; D002450:Cell Communication / Q000276:immunology; D002648:Child; D015331:Cohort Studies; D004268:DNA-Binding Proteins / Q000276:immunology; D020077:Endogenous Retroviruses / Q000235:genetics / Q000276:immunology; D015686:Gene Products, env / Q000276:immunology; D015789:HLA-A2 Antigen / Q000276:immunology; D006801:Humans; D008545:Melanoma / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control; D050778:NFATC Transcription Factors; D011379:Prognosis; D012878:Skin Neoplasms / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control; D012900:Smallpox Vaccine / Q000276:immunology*; D014157:Transcription Factors / Q000276:immunology; D014611:Vaccination; D014615:Vaccinia / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000956:Antigens, Viral; D001500:BCG Vaccine; D004268:DNA-Binding Proteins; D015686:Gene Products, env; D015789:HLA-A2 Antigen; D050778:NFATC Transcription Factors; D012900:Smallpox Vaccine; D014157:Transcription Factors